348 related articles for article (PubMed ID: 11281386)
1. Allogeneic peripheral blood stem cell transplantation results in less alteration of early T cell compartment homeostasis than bone marrow transplantation.
Tayebi H; Tiberghien P; Ferrand C; Lienard A; Duperrier A; Cahn JY; Lapierre V; Saas P; Kuentz M; Blaise D; Hervé P; Robinet E;
Bone Marrow Transplant; 2001 Jan; 27(2):167-75. PubMed ID: 11281386
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model.
Hartung G; Zeis M; Glass B; Dreger P; Steinmann J; Schmitz N; Uharek L
Bone Marrow Transplant; 2003 Jul; 32(1):49-56. PubMed ID: 12815478
[TBL] [Abstract][Full Text] [Related]
3. Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor.
Arseniev L; Tischler HJ; Battmer K; Südmeier I; Casper J; Link H
Bone Marrow Transplant; 1994 Nov; 14(5):791-7. PubMed ID: 7534162
[TBL] [Abstract][Full Text] [Related]
4. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation.
Siegert W; Beyer J; Kingreen D; Blasczyk R; Baurmann H; Schwella N; Schleicher J; Kirsch A; Huhn D
Bone Marrow Transplant; 1998 Sep; 22(6):579-83. PubMed ID: 9758347
[TBL] [Abstract][Full Text] [Related]
6. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
7. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
[TBL] [Abstract][Full Text] [Related]
8. [Reconstitution of peripheral blood lymphocytes in patients treated with bone marrow transplantation: comparison between allogeneic and autologous transplantation].
Parra C; Roldán E; Rodríguez C; Pérez de Oteyza J; Oteho E; López J; Maldonado MS; García Laraña J; Muñoz A; Odriozola J; Brieva JA
Med Clin (Barc); 1999 Jun; 113(1):1-5. PubMed ID: 10422068
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome.
Russell JA; Larratt L; Brown C; Turner AR; Chaudhry A; Booth K; Woodman RC; Wolff J; Valentine K; Stewart D; Ruether JD; Ruether BA; Klassen J; Jones AR; Gyonyor E; Egeler M; Dunsmore J; Desai S; Coppes MJ; Bowen T; Anderson R; Poon MC
Bone Marrow Transplant; 1999 Dec; 24(11):1177-83. PubMed ID: 10642805
[TBL] [Abstract][Full Text] [Related]
10. Transition of T cell receptor gamma/delta expressing double negative (CD4-/CD8-) lymphocytes after allogeneic bone marrow transplantation.
Yabe M; Yabe H; Hattori K; Hinohara T; Morimoto T; Kato S; Kusunoki A
Bone Marrow Transplant; 1994 Nov; 14(5):741-6. PubMed ID: 7889006
[TBL] [Abstract][Full Text] [Related]
11. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
[TBL] [Abstract][Full Text] [Related]
12. Low incidence of severe aGVHD and accelerating hemopoietic reconstitution in allo-BMT using lenograstim stimulated BM cells.
Ji S; Chen H; Wang H; Ma J; Pan S; Xue M; Zhu L; Liu J; Xiao M; Zhou L
Chin Med J (Engl); 2001 Feb; 114(2):191-5. PubMed ID: 11780205
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic aspects of allogeneic peripheral progenitor cells.
Glass B; Uharek L; Hartung G; Zeis M; Steinmann J; Dreger P; Krönke M; Schmitz N
Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S3-8. PubMed ID: 9712483
[TBL] [Abstract][Full Text] [Related]
14. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
[TBL] [Abstract][Full Text] [Related]
15. Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome.
Barge RM; Brouwer RE; Beersma MF; Starrenburg CW; Zwinderman AH; Hale G; Waldmann H; den Ottolander GJ; Falkenburg JH; Willemze R; Fibbe WE
Bone Marrow Transplant; 2001 May; 27(10):1053-8. PubMed ID: 11438820
[TBL] [Abstract][Full Text] [Related]
16. A prospective comparison of immune reconstitution in pediatric recipients of positively selected CD34+ peripheral blood stem cells from unrelated donors vs recipients of unmanipulated bone marrow from related donors.
Eyrich M; Leiler C; Lang P; Schilbach K; Schumm M; Bader P; Greil J; Klingebiel T; Handgretinger R; Niethammer D; Schlegel PG
Bone Marrow Transplant; 2003 Aug; 32(4):379-90. PubMed ID: 12900774
[TBL] [Abstract][Full Text] [Related]
17. Thymus-independent expansion of T lymphocytes in children after allogeneic bone marrow transplantation.
Honda K; Takada H; Nagatoshi Y; Akazawa K; Ohga S; Ishii E; Okamura J; Hara T
Bone Marrow Transplant; 2000 Mar; 25(6):647-52. PubMed ID: 10734299
[TBL] [Abstract][Full Text] [Related]
18. An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation.
Huang X; Guo N; Ren H; Zhang Y; Gao Z; Lu D
Chin Med J (Engl); 2003 May; 116(5):736-41. PubMed ID: 12875692
[TBL] [Abstract][Full Text] [Related]
19. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
[TBL] [Abstract][Full Text] [Related]
20. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
